Probiotic LP-LDL® shows promise for diabetes and prediabetes management

NCT ID NCT07373392

Not yet recruiting Disease control Sponsor: Aalborg University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily probiotic called LP-LDL® can improve cholesterol, blood sugar, inflammation, and memory in 210 adults with prediabetes, type 1, or type 2 diabetes who also have high cholesterol or triglycerides. Participants take either the probiotic or a placebo for 12 weeks, followed by a 4-week break. The goal is to see if this supplement can help manage disease and reduce related health risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia Insulin Resistance prediabetes syndrome type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE TYPE 1 DIABETE TYPE 2 PREDIABETES

Contacts and locations

Locations

Department of Health Science and Technology, Aalborg University

Gistrup, 9260, Denmark
Steno Diabetes Center Nordjylland

Gistrup, 9260, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.